SCHEMBL22609216

SCHEMBL22609216

CCOC(=O)c1nsc(C)c1[N+](=O)[O-]

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 3/20 0.44
▸ MEN1 O00255 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ RAB9A P51151 2/20 0.44
▸ NPC1 O15118 2/20 0.44
▸ MAPT P10636 4/20 0.41
▸ PTGS1 P23219 1/20 0.41
▸ PTGS2 P35354 1/20 0.41
▸ POLB P06746 2/20 0.40
▸ LMNA P02545 2/20 0.40
▸ ALDH1A1 P00352 5/20 0.40
▸ TSHR P16473 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ RECQL P46063 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.38
▸ MITF O75030 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22609200 0.73 GAA (0.44) GAAMEN1KMT2ARAB9ANPC1
SCHEMBL22609240 0.73 ALDH1A1 (0.50) GAAMEN1KMT2ARAB9ANPC1
SCHEMBL26101362 0.73 KDM4E (0.44) GAAMEN1KMT2ARAB9ANPC1
SCHEMBL3463863 0.72 PDE4D (0.50) MEN1KMT2ANPC1MAPTPTGS1
SCHEMBL18430514 0.70 MAPT (0.47) GAAMEN1KMT2ARAB9ANPC1
SCHEMBL27631417 0.70 ADORA3 (0.45) NPC1MAPTPTGS1PTGS2ALDH1A1
SCHEMBL16836849 0.70 MAPT (0.42) MEN1KMT2ARAB9ANPC1MAPT
SCHEMBL30910165 0.70 KDM4E (0.43) GAAMEN1KMT2ARAB9ANPC1
SCHEMBL58060 0.70 PTGS1 (0.42) GAAMEN1KMT2ARAB9ANPC1
SCHEMBL13214659 0.69 LMNA (0.43) MEN1KMT2ANPC1MAPTPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210171503-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF ORFAN BIOTECH SL (ES) 2021-06-10 — — US disclosed
EP-3731840-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF Orfan Biotech Inc. (US) 2020-11-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210171503-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF PNPO, XDH, GLS GAA 129/4885MEN1 3943/4885KMT2A 3407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback